Pricing Log in Create free account

Aardvark Therapeutics, Inc. (AARD) vs Cellectis S.A. (CLLS)

Aardvark Therapeutics, Inc. and Cellectis S.A. are both Biotechnology companies. Aardvark Therapeutics, Inc. and Cellectis S.A. are of similar size ($84.5M and $79.9M). Aardvark Therapeutics, Inc. has the higher net margin (0.00% vs −102.3%) and the lower return on invested capital (−4,986.2% vs 0.00%). Across the 13 metrics below, Aardvark Therapeutics, Inc. leads on 9 and Cellectis S.A. on 4.

Valuation

Metric AARD CLLS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 1.64 9.71
P/B 1.10 2.55 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 0.18 9.21
Earnings yield (84.92%) (62.89%) (33.15%)
Free cash flow yield (84.17%) (44.14%) (25.50%)

Profitability

Metric AARD CLLS Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (90.88%) 0.00%
Net margin 0.00% (102.34%) 0.00%
Free cash flow margin 0.00% (68.63%) 0.00%
Return on equity (66.02%) (94.54%) (56.36%)
Return on assets (61.06%) (21.02%) (48.04%)
Return on invested capital (4,986.18%) 0.00% 0.00%

Growth

Metric AARD CLLS Biotechnology median
Revenue growth (TTM) — 0.61% 6.02%
EPS growth (last fiscal year) 43.11% (63.41%) 30.26%
Revenue growth, 5-year CAGR — (0.70%) 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric AARD CLLS Biotechnology median
Debt to equity 0.00 1.79 0.00
Current ratio 12.63 1.37 4.72
Net debt to EBITDA 1.72 9.54 0.96

Dividend

Metric AARD CLLS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric AARD CLLS Biotechnology median
Market cap 84.47m 79.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack